Liminatus Pharma, Inc. (LIMNW)Cerritos, United States | NasdaqCM
0.05 USD
|
Hot Take ↕ | July 11, 2026, 4:37 a.m. EDT
The immediate outlook is severely bearish due to a catastrophic liquidity crisis. The stock is trading at $0.0501, which coincides exactly with its 52-week high and low, indicating a complete lack of trading volume and market participation. This stagnation is confirmed by the news of an appeal against Nasdaq delisting for a market value shortfall, suggesting the company cannot meet listing requirements. Fundamentally, the business is deteriorating rapidly with negative book value (-$0.003), massive operating cash outflows (-$11.8M), and a current ratio below 1.0, signaling imminent insolvency. There is no dividend to provide any cushion, and the price action shows no signs of recovery, making this a clear sell/avoid scenario. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.000852 |
| AutoTheta | 0.001683 |
| AutoETS | 0.003130 |
| MSTL | 0.004488 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 0.12 |
| Ljung-Box p | 1.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 40.02 |
| Attribute | Value |
|---|---|
| Beta | 0.74 |
| Previous Name | Liminatus Pharma, LLC |
| Website | https://liminatuspharma.com |
| Attribute | Value |
|---|---|
| Address1 | 12,611 Hiddencreek Way |
| Address2 | Unit C |
| Ask | 0.1706 |
| Ask Size | 1 |
| Beta | 0.744 |
| Bid | 0.31 |
| Bid Size | 10 |
| Book Value | -0.003 |
| City | Cerritos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0501 |
| Current Ratio | 0.962 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0501 |
| Day Low | 0.0501 |
| Display Name | Liminatus Pharma |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0501 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0501 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.0501 - 0.0501 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 29,428,508 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,025-05-01 |
| Language | en-US |
| Long Business Summary | Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California. |
| Long Name | Liminatus Pharma, Inc. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_570895157 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -11,002,705 |
| Open | 0.0501 |
| Operating Cashflow | -11,819,214 |
| Operating Margins | 0.0 |
| Phone | 213 273 5453 |
| Prev Name | Liminatus Pharma, LLC |
| Previous Close | 0.0501 |
| Price Hint | 4 |
| Price To Book | -16.699999 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.66 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.0501 |
| Regular Market Day Low | 0.0501 |
| Regular Market Day Range | 0.0501 - 0.0501 |
| Regular Market Open | 0.0501 |
| Regular Market Previous Close | 0.0501 |
| Regular Market Price | 0.0501 |
| Regular Market Time | 1,783,713,600 |
| Regular Market Volume | 75 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | Liminatus Pharma, Inc. Warrants |
| Source Interval | 15 |
| State | CA |
| Symbol | LIMNW |
| Total Cash | 1,907,674 |
| Total Cash Per Share | 0.043 |
| Total Debt | 1,442,500 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 75 |
| Website | https://liminatuspharma.com |
| Zip | 90,703 |